Testing a lab test to identify pancreatic cyst tumor type
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study builds a “molecular marker” lab model using pancreatic cyst fluid taken during planned pancreatic surgery. It aims to help tell which pancreatic cystic tumors are which, based on fluid analysis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- Scans (endoscopic ultrasound, CT, or MRI) show a pancreatic cystic mass that may be a tumor
- You are willing to have planned radical (complete) surgical removal of the cystic tumor
- Cyst fluid can be collected from the cyst during the procedure
- You have not had tumor treatments like chemotherapy, radiation, or immunotherapy before surgery
- You have not taken antibiotics in the 1 week before surgery, and you agree to research consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special technique called single-cell sequencing to study pancreatic cancer cells from patients whose tumors can be surgically removed or are on the edge of being removable. Participation may help researchers understand the disease better and could guide future treatments.
This study tests whether a blood test that looks at DNA changes (ctDNA methylation) can help predict how pancreatic cancer will behave and guide treatment decisions. It includes people with suspected pancreatic cancer who are planning surgery or a biopsy.
This study looks at a special analysis of your blood (called cfDNA fragmentomics) to help find and tell apart certain early pancreatic tumors. If you’re having surgery for one of the listed solid pancreatic tumors, this trial may use your blood samples to improve diagnosis.
This study looks at using a special blood test (ctDNA MRD) to track how well the tumor responds to chemotherapy before surgery for pancreatic cancer. It may help doctors decide if the treatment is working and guide next steps.
This trial uses a blood test (called cfDNA) to look for early signs of pancreatic cancer. It compares results from people with pancreatic cancer, precancerous changes, non-cancerous pancreatic conditions, and healthy individuals to improve early detection.
This trial collects pancreatic cyst fluid or tissue to study the genes of these tumors. The goal is to better understand pancreatic cysts and improve future treatments.
Hear when a new Pancreatic Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.